Interesting, I purchased 300 shares (I don’t do options) before earnings this month, which were good. A month and a half ago I gave grok a prompt to give me biotech companies with a high chance of m&a, with approved products that have real sales, and focus on indications where there is a lot of interest of big pharma (oncology always an obvious one). It gave me three names which I put on my watchlist, SNDX TVTX INSM. Look at what these stocks did in the last month and their last quarterly earnings. I decided to invest in SNDX. I obviously do further DD, yes that includes asking more questions on grok and chat, but also verifying what it says and independent research. I look at various stuff but other than the obvious, also the inbound and outbound licenses. The production cost of the product. Here it’s a small molecule which is great. Management obviously. Anyone who says aerotyne hasn’t given this even a couple of minutes. This is a real pharmaceutical product used to treat lukemia patients and sold by their partner Incyte. So product which is sold and makes money, good partnerships, good license agreements, good pipeline and solid management. Also this is biotech, it’s almost exclusively inside and institutional holdings, almost no retail. Never going to be a meme stock, just steady growth with possible jumps if pipeline is successful until some pharma buys them for a very nice premium

---

I love that these announcements always conveniently happen after a red Friday

---

You’re a legend for the gains, be safe and leave the party when you are ready so those gains live forever!

---

Looks like my UAMY is fucked for a year then

---

I’m also bullish, but I didn’t think about the possibility of any M&A action as they seem pretty strong as a standalone. Here’s my DD: https://bioequitywatch.substack.com/p/dd-syndax-pharmaceuticals-sndx

---

It means buying more shares when a stock you already own drops. The idea is to lower your weighted average cost. Eg, you buy 100 stock at $100 each, your average price is $100. If the stock drops to 90 and you buy 50 more, you now have an average price of $96.67.

---

A milkshake https://preview.redd.it/0efo2ayw090g1.png?width=1450&format=png&auto=webp&s=0a757b113a6eb97bc268254f39f958449f333690

---

I think you are misunderstanding. Off label use is not the concern. It literally would make zero sense for a practicing physician to not prescribe a DIABETIC patient Mounjaro or Ozempic. This simply puts all liability on the physician for no reason. I have never seen it happen. The idea that subQ will die because patients will not take these drugs and instead will find someone instead to prescribe oral formulations for their diabetes is bananas. Rybelsus already exists. GLP-1 agonists are adjunct treatments. Nobody is upending their treatment plan and no doctor is going to risk their patient’s well being and legal ramifications.

---

and if it doesn't take you above the poverty line it's not "Basic" either. it's literally just a shut the fuck up allowance, or more like you tell your kids you're going to McDonald's all the way home so they stop asking

---

He lives in a fantasy land.

---